Safety & Efficacy of Qurs e Fishar in Mild to Moderate Hypertensive Patients in Pakistan
Recruiting · NCT06852079 · Interventional (participants receive a specific treatment) · Lead sponsor: Abdul Bari
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
The herbal medicine Qurs-e-Fishar to treat mild to moderate High blood pressure or hypertension comprises of Rauwolfia serpentina. A product of Hamdard Laboratories (Waqf) Pakistan. A Phase III Safety \& Efficacy Open-label, Single-Arm, Interventional, Multicenter, Study in mild to moderate hypertensive, adults (30 to 60 years of age) prescribed with study product for 12 weeks (84 days). Primary End Points: 1. Reduction in diastolic blood pressure less than 130 / 80 mmHg at the end of the study period (accepted by WHO) or if there was a fall of 20 / 10 mmHg or more in diastolic blood pressure as compared to baseline. 2. Type, frequency and severity of ADRs during the study period. Secondary End Points: 1\. Compliance of the prescribed study medication.
Who can take part
Inclusion criteria
- Ability to sign ICD
- Participant(s) are willing and able to fulfill the requirements of the study protocol
- Mild to moderate hypertensive
- Mild hypertension range (140-159/90-99 mm Hg)
- Moderate hypertension range (160-179/100-109 mm Hg)
- Be between the age of 30 to 60 year
Exclusion criteria
- Patients with recent history of following will be excluded:
- Severe hypertension,
- Congestive cardiac failure,
- Left ventricular failure,
- Myocardial ischemia,
- Renal failure or
- Cerebrovascular accidents
Where it is running
1 location listed.
- Taj Medical Complex, Hamdard University Hospital - Karachi, Sindh, Pakistan